Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842800 · ClinicalTrials.gov registry record · Early Phase 1
Characterizing Clinical and Pharmacological Neuroimaging Biomarkers
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 143
- Enrollment target
NCT03842800: Completed Early Phase 1 study, sponsored by Yale University.
NCT03842800 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 143 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (170% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03842800, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
This study is part of a larger overall study that seeks to characterize clinical and pharmacological neuroimaging biomarkers. The purpose of this registered protocol is understand the effect of emotion on cognitions by specifically examining the effect of reward processing on working memory in patients with schizophrenia.
Primary Outcome
The tool used to measure working memory (WM) is a spatial working memory task. We measure angular accuracy of spatial working memory, and better accuracy is indicated by a lower angular distance. Subjects are asked to centrally fixate, and a circle appears on the screen briefly, and then disappears. Afterwards they see a gray circle that is linked to a joystick and are asked to move the gray circle to where they best remembered the initial circle to be. We care about the angular distance between
Interventions
- DRUG Ketamine
- OTHER MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2018-08-31 |
| Phase | Early Phase 1 |
What the finished NCT03842800 record still lists
NCT03842800 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (170% higher).
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT03842800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03842800 about?
NCT03842800 is a clinical study titled "Characterizing Clinical and Pharmacological Neuroimaging Biomarkers". This study is part of a larger overall study that seeks to characterize clinical and pharmacological neuroimaging biomarkers. The purpose of this registered protocol is understand the effect of emotion on cognitions by specifically examining the effect of reward processing on working memory in patie...
What is the current status of trial NCT03842800?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 143 participants. The study started on 2013-04-01. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT03842800?
The interventions under investigation include: Ketamine (DRUG), MRI (OTHER).
Who is sponsoring clinical trial NCT03842800?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03842800's enrollment target sits among peer trials
143 112th of 2000 higher than 1,887 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI